Diagnostics

VMX 2025: A Record-Breaking Celebration of Innovation, Education and Thought Leadership in Veterinary Medicine

Breakthroughs in veterinary medicine, immersive hands-on experiences and Academy Award-winning actor and director Kevin Costner headline the world's largest and…

11 months ago

Co-Diagnostics, Inc. to Exhibit at BioUtah’s 2025 Life Sciences Day on the Hill

SALT LAKE CITY, Jan. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company…

11 months ago

Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

HENDERSON, Nev., Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the…

11 months ago

Top Product Development Firm Reports Record-Breaking Year Helping Companies Develop AI-Powered and Connected Hardware

OTTAWA, ON, Jan. 30, 2025 /PRNewswire/ - How one of the largest end-to-end product development firms in North America accelerated go-to-market…

11 months ago

Kansas City Metro Selected by Groundbreaking Australian Animal Health Tech Company for North American HQ

The animal health intelligence company, Ceres Tag, is expanding into the United States for the distribution of its first-of-its-kind direct-to-satellite…

11 months ago

Medrio’s Launches AI-Enabled Reporting, Tackling Increasing Data Challenges in Clinical Trials

SAN FRANCISCO, Jan. 29, 2025 /PRNewswire/ -- Medrio, a global leader in clinical trial technology, today announced the release of AI-enabled…

11 months ago

Danaher Reports Fourth Quarter and Full Year 2024 Results

WASHINGTON, Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and…

11 months ago

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+…

11 months ago

Change to the Roche Enlarged Corporate Executive Committee

Basel, 29 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company…

11 months ago

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset,…

11 months ago